Want to see IEX full AI Analyst Report?
Earnings Data
Report Date
Jul 29, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
2.11Last Year’s EPS
2.07Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call skewed positive: management reported better-than-expected Q1 results, raised full-year organic growth and EPS guidance, highlighted strong HST order and revenue momentum with meaningful backlog and margin expansion, maintained aggressive share repurchases and an active bolt-on M&A pipeline, and ended the quarter with strong liquidity. Offsetting items include mixed short-cycle industrial performance, pressure in life sciences and some gross margin/mix headwinds; free cash flow was modestly lower in the seasonally weak quarter. On balance, the positive operational progress, upgraded guidance and financial optionality outweigh the contained challenges.Company Guidance
Raised Full-Year Organic Growth Guidance
Full-year 2026 organic growth guidance increased to 3%–4% (up from 1%–2%), driven by stronger backlog and HST momentum.
Strong Q1 Organic Revenue and Orders
Q1 organic sales growth of 5% and consolidated organic orders growth of ~10% year-over-year, with orders above expectations.
Health & Science Technologies (HST) Outperformance
HST organic orders +17% and organic revenue +11% in Q1; HST adjusted EBITDA margin expanded ~100 bps YoY. Management cites durable secular drivers (data center, semiconductor, space & defense, pharma).
Margin Expansion at Consolidated Level
Adjusted EBITDA margin of 26% in Q1, a 50 basis-point expansion year-over-year, driven by productivity improvements, volume leverage and price/cost actions.
Improved Visibility and Backlog
Notable backlog build in HST providing greater visibility into the remainder of 2026 and into 2027, supporting confidence in multi-year growth runway.
Capital Allocation and Liquidity Strength
Repurchased $76 million of shares in Q1 and plan to maintain that quarterly pace for 2026; paid $53 million in dividends; ended quarter with ~ $1.1 billion liquidity and gross leverage ~2x.
Updated EPS Outlook
Raised 2026 adjusted EPS guidance by $0.20 to $8.35–$8.55, implying mid- to high-single-digit year-over-year growth; Q2 adjusted EPS guide of $2.07–$2.12.
Active Bolt-On M&A Pipeline
Management reports an active pipeline for bolt-on M&A while maintaining current share repurchase cadence; acquired businesses contributing to growth.
IEX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IEX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $204.63 | $216.57 | +5.83% |
Feb 04, 2026 | $200.89 | $211.50 | +5.28% |
Oct 29, 2025 | $165.75 | $172.16 | +3.86% |
Jul 30, 2025 | $183.06 | $162.40 | -11.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Idex Corporation (IEX) report earnings?
Idex Corporation (IEX) is schdueled to report earning on Jul 29, 2026, After Close (Confirmed).
What is Idex Corporation (IEX) earnings time?
Idex Corporation (IEX) earnings time is at Jul 29, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IEX EPS forecast?
IEX EPS forecast for the fiscal quarter 2026 (Q2) is 2.11.